Osaic Holdings’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,000
| Closed | -$720 | – | 7938 |
|
|
2025
Q3 | $720 | Hold |
2,000
| – | – | ﹤0.01% | 7457 |
|
|
2025
Q2 | $720 | Hold |
2,000
| – | – | ﹤0.01% | 7261 |
|
|
2025
Q1 | $520 | Hold |
2,000
| – | – | ﹤0.01% | 6982 |
|
|
2024
Q4 | $1.12K | Hold |
2,000
| – | – | ﹤0.01% | 6808 |
|
|
2024
Q3 | $1.2K | Hold |
2,000
| – | – | ﹤0.01% | 6788 |
|
|
2024
Q2 | $5.4K | Sell |
2,000
-1,000
| -33% | -$3.77K | ﹤0.01% | 6127 |
|
|
2024
Q1 | $15.4K | Buy |
3,000
+1,000
| +50% | +$3.24K | ﹤0.01% | 5508 |
|
|
2023
Q4 | $1.07K | Hold |
2,000
| – | – | ﹤0.01% | 6728 |
|
|
2023
Q3 | $1.32K | Buy |
+2,000
| New | +$2.02K | ﹤0.01% | 6755 |
|
|
2022
Q4 | – | Sell |
-1,100
| Closed | -$1K | – | 7244 |
|
|
2022
Q3 | $1K | Hold |
1,100
| – | – | ﹤0.01% | 6973 |
|
|
2022
Q2 | $2K | Hold |
1,100
| – | – | ﹤0.01% | 6867 |
|
|
2022
Q1 | $3K | Hold |
1,100
| – | – | ﹤0.01% | 6727 |
|
|
2021
Q4 | $7K | Hold |
1,100
| – | – | ﹤0.01% | 6459 |
|
|
2021
Q3 | $9K | Buy |
+1,100
| New | +$11.9K | ﹤0.01% | 6269 |
|
Osaic Holdings's ELEV Position: Q4 2025 in Review
Osaic Holdings sold out of Elevation Oncology (ELEV) in Q4 2025, closing a stake of 2,000 shares — an estimated $720 sold.
Osaic Holdings first reported a position in ELEV in Q3 2021 and held it in 14 quarters. The position peaked at $15.4K in Q1 2024. 0 funds tracked by Wall St. Rank hold ELEV as of Q4 2025.
- Osaic Holdings reported no remaining Elevation Oncology position as of Q4 2025 after selling out during the quarter.
- Osaic Holdings sold 2,000 Elevation Oncology shares in Q4 2025, an estimated $720.
- Osaic Holdings first reported a position in Elevation Oncology in Q3 2021 and held it in 14 quarters.
- Osaic Holdings's Elevation Oncology position peaked at $15.4K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2025.
Based on Osaic Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.